Business Context and Reporting Period
MedTech Acquisition Corporation, a special purpose acquisition company, filed this Form 8-K regarding its August 8, 2023 special meeting of stockholders. Stockholders voted on the proposed business combination with TriSalus Life Sciences, Inc. and related transaction proposals. The report was signed August 9, 2023.
Key Financial and Transaction Metrics
| Metric | Reported amount |
|---|---|
| Shares represented at the special meeting | 7,154,021, representing 96.7% of voting power and constituting a quorum |
| Class A shares elected for redemption | 890,499 |
| Estimated funds withdrawn from the Trust Account | Approximately $9.42 million |
| Estimated redemption value per share | Approximately $10.58 |
| Revenue, profit, cash flow, margins, debt and liquidity | The filing text does not provide clear operating or balance-sheet values for TriSalus or MedTech. |
Material Changes Versus the Prior Comparable Period
- No period-over-period financial results are reported.
- All proposals submitted at the special meeting were approved, including the business combination, charter amendments, governance matters, equity incentive plans, Nasdaq-related proposal and director nominations.
- Redemption elections reduced the cash expected to remain in the Trust Account by approximately $9.42 million, subject to completion of the business combination.
Guidance, Outlook, Risks and Unusual Items
- The business combination and related transactions were expected to close subject to satisfaction or waiver of the conditions described in the proxy statement.
- Following closing, the combined company expected its common stock and warrants to trade on Nasdaq under the symbols “TLSI” and “TLSIW,” respectively.
- Closing risks include failure to meet minimum-cash requirements after redemptions, failure to obtain governmental or regulatory approvals, failure of the contemplated Series A Convertible Stock private placement, termination of the merger agreement and failure to complete the transaction by the business combination deadline.
- Additional risks include potential legal proceedings, disruption to TriSalus operations and relationships, reimbursement changes, inability to obtain future financing, Nasdaq delisting risk, transaction costs and failure to realize expected benefits or pro forma results.
- The filing contains forward-looking statements and cautions that actual results may differ materially; neither company undertook to update those statements.
Investor Verification Points
- Verify whether all remaining closing conditions were satisfied and whether the business combination with TriSalus closed.
- Confirm the final number of redeemed shares, cash remaining in the Trust Account and any additional financing obtained.
- Confirm the effectiveness of the charter amendments, Series A Convertible Stock financing and related transaction documents.
- Verify the combined company’s final Nasdaq listing status and trading symbols.
- Review subsequent SEC filings for TriSalus’s revenue, operating losses, cash burn, debt, liquidity and material contingencies, which are not provided in this filing.